MediciNova, Inc.

Rentabilité sur six mois: -28.88%
Rendement en dividendes: 0%
Secteur: Healthcare

1.33 $

0 $ 0%
1.13 $
2.38 $

paper.min_max_per_year

Calendrier des promotions MediciNova, Inc.

À propos de l'entreprise MediciNova, Inc.

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

Paramètres de base

IPO date
2005-02-08
ISIN
US58468P2065
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт

Grade

Sous-estimation
Nom Signification Grade
P/S 71.61 1
P/BV 1.97 7
P/E 0 0
Efficacité
Nom Signification Grade
ROA -18.09 0
ROE -19.24 0
ROIC 0 0
Dividendes
Nom Signification Grade
Rendement en dividendes 0 0
DSI 0 0
Croissance moyenne du dividende 0 0
Devoir
Nom Signification Grade
Debt/EBITDA -0.0196 10
Debt/Ratio 0.0035 10
Debt/Equity 0.0642 10
Impulsion de croissance
Nom Signification Grade
Rentabilité Revenue, % 24.6 4
Rentabilité Ebitda, % -29.43 0
Rentabilité EPS, % -27.77 0

paper.price.prices

Prix Common.min. Common.max. Changement paper.changes_in_industry paper.changes_in_index
common.calendar.number_days.1 1.33 $ 0 $ 0 $ 0 % 0 % 0 %
common.calendar.number_days.7d 1.36 $ 0 $ 0 $ -2.21 % 0 % 0 %
common.calendar.number_days.30d 1.41 $ 1.33 $ 1.38 $ -5.67 % 0 % 0 %
common.calendar.number_days.90d 1.38 $ 1.32 $ 1.59 $ -3.62 % 0 % 0 %
common.calendar.number_days.180d 1.87 $ 1.2 $ 2.05 $ -28.88 % 0 % 0 %
common.calendar.number_days.1y 1.37 $ 1.13 $ 2.38 $ -2.92 % 0 % 0 %
common.calendar.number_days.3y 2.17 $ 1.13 $ 2.66 $ -38.71 % 0 % 0 %
common.calendar.number_days.5y 6.26 $ 1.13 $ 11 $ -78.75 % 0 % 0 %
common.calendar.number_days.10y 1.13 $ 1.13 $ 13.91 $ 117.7 % 0 % 0 %
common.calendar.number_days.ytd 2.05 $ 1.2 $ 2.16 $ -35.12 % 0 % 0 %

Principaux propriétaires

Entreprises similaires



Gestion d'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Dr. Yuichi Iwaki M.D., Ph.D. Co-Founder, President, CEO & Executive Director 907.26k 1950 (75 années)
Dr. Kazuko Matsuda M.D., M.P.H., Ph.D. Chief Medical Officer & Director 649.05k 1966 (59 années)
Mr. Jason J. Kruger CPA CFO & Principal Financial Officer N/A 1978 (47 années)
Dr. David H. Crean M.B.A., Ph.D. Chief Business Officer N/A 1965 (60 années)
Mr. John O'Neil CPA Controller

Informations sur l'entreprise

Adresse: United States, La Jolla. CA, 4275 Executive Square - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.medicinova.com